# Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma

> **NCT03657420** · PHASE1 · WITHDRAWN · sponsor: **Massachusetts General Hospital**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** ABI-009
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03657420
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-05-30
- **Primary completion:** 2021-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding withdrawn by sponsor
- **Last updated:** 2019-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03657420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03657420, "Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03657420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*